Takara Bio Inc.
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Private
- Established
- 1984-01-01
- Employees
- 101
- Market Cap
- -
- Website
- https://www.takarabio.com
Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2017-08-17
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Takara Bio Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT03252808
- Locations
- 🇯🇵
Clinical Site, Osaka, Japan
Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients with Synovial Sarcoma
- First Posted Date
- 2017-08-15
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Takara Bio Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03250325
- Locations
- 🇯🇵
National Hospital Organization Osaka National Hospital, Osaka, Japan
🇯🇵Mie University Hospital, Tsu, Mie, Japan
🇯🇵National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Takara Bio Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT03155191
- Locations
- 🇯🇵
The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan
🇯🇵Hokkaido University Hospital, Sapporo-shi, Hokkaido, Japan
🇯🇵University Of Fukui Hospital, Yoshida, Fukui, Japan
A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-05-15
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Takara Bio Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT03153085
- Locations
- 🇯🇵
Clinical Site, Ōsaka, Japan
A Study of TBI-1401(HF10) in Patients With Solid Tumors With Superficial Lesions
- First Posted Date
- 2015-04-28
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Takara Bio Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT02428036
- Locations
- 🇯🇵
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma
- First Posted Date
- 2014-10-23
- Last Posted Date
- 2018-09-26
- Lead Sponsor
- Takara Bio Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT02272855
- Locations
- 🇺🇸
Clinical Site, Salt Lake City, Utah, United States
Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-11-20
- Last Posted Date
- 2019-05-23
- Lead Sponsor
- Takara Bio Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT01017185
- Locations
- 🇺🇸
Mary Crowley Cancer Research Center, Dallas, Texas, United States
🇺🇸Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇺🇸Oregon Health and Science University, Portland, Oregon, United States
© Copyright 2024. All Rights Reserved by MedPath